Former Pharmion Principals Start Over In Oncology With Clovis
This article was originally published in The Pink Sheet Daily
Executive Summary
New, privately held biotech will focus on acquiring, developing and commercializing other companies’ oncology assets.
You may also be interested in...
Panel: Oncology Business Models Determined By Capital And Culture
Panelists with a variety of strategic motives met to discuss the pros and cons of business models at the Cancer Progress Meeting in New York City. The group represented both new and old firms, including some that perform research and some that license drugs.
Clovis Oncology Seeks $149.5 Million IPO
The Colorado cancer drug maker is seeking financing through the public capital markets.
Clovis Oncology Seeks $149.5 Million IPO
The Colorado cancer drug maker is seeking financing through the public capital markets.